Association of Frequency and Duration of Aspirin Use and Hormone Receptor Status With Breast Cancer Risk
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
CONTEXT: Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with a decrease in the risk of several cancers, including breast cancer. NSAIDs inhibit cyclooxygenase activity and thereby reduce prostaglandin synthesis; prostaglandins stimulate aromatase gene expression and thereby stimulate estrogen biosynthesis. Given the importance of estrogen in the pathogenesis of breast cancer, the ability of aspirin and other NSAIDs to protect against breast cancer could vary according to hormone receptor status. OBJECTIVES: To determine the association between the frequency and duration of use of aspirin and other NSAIDs and breast cancer risk and to investigate whether any observed association is more pronounced for women with hormone receptor-positive breast cancers. DESIGN, SETTING, AND PATIENTS: Population-based case-control study of women with breast cancer, including in-person interviews conducted on Long Island, NY, during 1996-1997 (1442 cases and 1420 controls). MAIN OUTCOME MEASURE: Incident invasive and in situ breast cancer by aspirin and NSAID use and hormone receptor status. RESULTS: Ever use of aspirin or other NSAIDs at least once per week for 6 months or longer was reported in 301 cases (20.9%) and 345 controls (24.3%) (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.66-0.97 for ever vs nonusers). The inverse association was most pronounced among frequent users (> or =7 tablets per week) (OR, 0.72; 95% CI, 0.58-0.90). The results for ibuprofen, which was used by fewer women on a regular basis, were generally weaker (OR, 0.78; 95% CI, 0.55-1.10 for <3 times per week vs OR, 0.92; 95% CI, 0.70-1.22 for > or =3 times per week). Use of acetaminophen, an analgesic that does not inhibit prostaglandin synthesis, was not associated with a reduction in the incidence of breast cancer. The reduction in risk with aspirin use was seen among those with hormone receptor-positive tumors (OR, 0.74; 95% CI, 0.60-0.93) but not for women with hormone receptor-negative tumors (OR, 0.97; 95% CI, 0.67-1.40). CONCLUSION: These data add to the growing evidence that supports the regular use of aspirin and other NSAIDs (which may operate through inhibition of estrogen biosynthesis) as effective chemopreventive agents for breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Biostatistics: A Foundation for Analysis in the Health Sciences.
Rosenfeld, B., & Daniel, W. W. (1984) · Journal of the American Statistical Association · doi:10.2307/2288760 · Cited by 2,834
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021633 · Cited by 1,136
Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study
Schreinemachers, D. M., & Everson, R. B. (1994) · Epidemiology · doi:10.1097/00001648-199403000-00003 · Cited by 736
Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis
Derry, S. (2000) · BMJ · doi:10.1136/bmj.321.7270.1183 · Cited by 677
Cyclooxygenase 2: a molecular target for cancer prevention and treatment
Subbaramaiah, K., & Dannenberg, A. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00043-3 · Cited by 649
Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., et al. (1996) · PubMed · Cited by 545
Zhao, Y. D., Agarwal, V. R., Mendelson, C. R., & Simpson, E. R. (1996) · Endocrinology · doi:10.1210/en.137.12.5739 · Cited by 434
Langman, M. J. S. (2000) · BMJ · doi:10.1136/bmj.320.7250.1642 · Cited by 419
Farrow, D. C., Vaughan, T. L., Hansten, P. D., et al. (1998) · PubMed · Cited by 416
Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G. L., Loar, A., Rodabough, R. J., White, E., & McTiernan, A. (2003) · PubMed · Cited by 411
Sanmuganathan, P. S., Ghahramani, P., Jackson, P. R., Wallis, E. J., & Ramsay, L. E. (2001) · Heart · doi:10.1136/heart.85.3.265 · Cited by 410
Aspirin use and chronic diseases: a cohort study of the elderly.
Paganini-Hill, A., Chao, A., Ross, R. K., & Henderson, B. E. (1989) · BMJ · doi:10.1136/bmj.299.6710.1247 · Cited by 396
Nonsteroidal Antiinflammatory Drugs and Breast Cancer
Harris, R. E., Namboodiri, K. K., & Farrar, W. B. (1996) · Epidemiology · doi:10.1097/00001648-199603000-00017 · Cited by 345
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
Howe, L. R., Subbaramaiah, K., Brown, A. M., & Dannenberg, A. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080097 · Cited by 322
Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
Brueggemeier, R. W., Quinn, A. L., Parrett, M. L., Joarder, F. S., Harris, R. E., & Robertson, F. M. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00050-6 · Cited by 238
Gammon, M. D., Neugut, A. I., Santella, R. M., Teitelbaum, S. L., Britton, J. A., Terry, M. B., Eng, S. M., Wolff, M. S., Stellman, S. D., Kabat, G. C., et al. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1016387020854 · Cited by 216
Self-citationSharpe, C. R., Collet, J.-P., McNutt, M., Belzile, E., Boivin, J.-F., & Hanley, J. A. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1119 · Cited by 187
Prospective Study of Regular Aspirin Use and the Risk of Breast Cancer
Egan, K. M., Stampfer, M. J., Giovannucci, E., Rosner, B. A., & Colditz, G. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.988 · Cited by 183
Elvin, J. A., Yan, C., & Matzuk, M. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180295197 · Cited by 182
Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer.
Harris, R. E., Kasbari, S., & Farrar, W. B. (1999) · Oncology Reports · doi:10.3892/or.6.1.71 · Cited by 175
Epidemiology of Non-Steroidal Anti-Inflammatory Drugs and Cancer
Baron, J. A. (2003) · Progress in Experimental Tumor Research · doi:10.1159/000071364 · Cited by 161
Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer.
Johnson, T., Anderson, K. E., Lazovich, D., & Folsom, A. R. (2002) · PubMed · Cited by 118
Nonsteroidal anti-inflammatory drug use and breast cancer risk.
Cotterchio, M., Kreiger, N., Sloan, M., & Steingart, A. B. (2001) · PubMed · Cited by 100
Nonsteroidal Anti-inflammatory Drugs and Cancer
Rosenberg, L. A. (1995) · Preventive Medicine · doi:10.1006/pmed.1995.1018 · Cited by 71
Cited by
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Cook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796
The impact of comorbidity on cancer survival: a review
Sogaard, M., W. Thomsen, R., Bossen, Henrik Toft Sørensen, H., & Nørgaard, M. (2013) · Clinical Epidemiology · doi:10.2147/clep.s47150 · Cited by 603
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Ulrich, C. M., Bigler, J., & Potter, J. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1801 · Cited by 548
Aromatase Inhibitors in the Treatment of Breast Cancer
Brueggemeier, R. W., Hackett, J. C., & Diaz-Cruz, E. S. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0015 · Cited by 484
Metadata
- Authors
- Terry, M. B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-05-26
- Volume
- 291
- Issue
- 20
- Pages
- 2433
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2067608498
- Cited by
- 271
- References
- 28
- FWCI
- 19.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.